Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward F Patz

Showing results (41-50 of 101) with videos related to

Pageof 11
Sort By:
The Lancet. Oncology|March 25, 2016
Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trialEdward F Patz, Erin Greco, Constantine Gatsonis, et al.
AJR. American Journal of Roentgenology|February 22, 2007
Practical approach to diagnostic CT combined with PETTerence Z Wong, Erik K Paulson, Rendon C Nelson, et al.
Cancer Informatics|March 24, 2009
Characterising phase variations in MALDI-TOF data and correcting them by peak alignmentSimon M Lin, Richard P Haney, Michael J Campa, et al.
Radiology|November 23, 2021
Mediastinal Lymphadenopathy in the National Lung Screening Trial (NLST) Is Associated with Interval Lung CancerHamid Chalian, Holman Page McAdams, Youkyung Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancerPieter E Postmus, Elisabeth Brambilla, Kari Chansky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2010
Complement factor H autoantibodies are associated with early stage NSCLCNita Amornsiripanitch, Shaolin Hong, Michael J Campa, et al.
Frontiers in Oncology|May 10, 2019
Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary LesionsTina D Tailor, Xiayu Rao, Michael J Campa, et al.
Cancer|October 6, 2007
Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancerLuke F M Hoagland, Michael J Campa, Elizabeth B Gottlin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 16, 2021
Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening TrialDae Hee Han, Fenghai Duan, Yanning Wu, et al.
Molecular Cancer Therapeutics|March 30, 2023
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103Ryan T Bushey, Ruchi Saxena, Michael J Campa, et al.
Pageof 11

Showing results (41-50 of 101) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|March 25, 2016
Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trialEdward F Patz, Erin Greco, Constantine Gatsonis, et al.
AJR. American Journal of Roentgenology|February 22, 2007
Practical approach to diagnostic CT combined with PETTerence Z Wong, Erik K Paulson, Rendon C Nelson, et al.
Cancer Informatics|March 24, 2009
Characterising phase variations in MALDI-TOF data and correcting them by peak alignmentSimon M Lin, Richard P Haney, Michael J Campa, et al.
Radiology|November 23, 2021
Mediastinal Lymphadenopathy in the National Lung Screening Trial (NLST) Is Associated with Interval Lung CancerHamid Chalian, Holman Page McAdams, Youkyung Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancerPieter E Postmus, Elisabeth Brambilla, Kari Chansky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2010
Complement factor H autoantibodies are associated with early stage NSCLCNita Amornsiripanitch, Shaolin Hong, Michael J Campa, et al.
Frontiers in Oncology|May 10, 2019
Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary LesionsTina D Tailor, Xiayu Rao, Michael J Campa, et al.
Cancer|October 6, 2007
Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancerLuke F M Hoagland, Michael J Campa, Elizabeth B Gottlin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 16, 2021
Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening TrialDae Hee Han, Fenghai Duan, Yanning Wu, et al.
Molecular Cancer Therapeutics|March 30, 2023
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103Ryan T Bushey, Ruchi Saxena, Michael J Campa, et al.
Pageof 11